SASAKO, Takayoshi

From Tokyo, now in Montreal. Working on diabetes and endocrinology, and now on data science as well.

[SASAKO, Takayoshi @sasakotaka]

@ASBMR @MiguelGBorda2 @marc_p_sim @DrGustavoDuque @FIFAWorldCup Now you can find it typeset: https://t.co/8HmnhDe1rT

[SASAKO, Takayoshi @sasakotaka]

Hi all, now you can find our review on osteosarcopenia in JBMR published by @ASBMR. This is a collaboration with @MiguelGBorda2, @marc_p_sim, and @DrGustavoDuque, and all of us are from countries that advanced to the knockout stage @FIFAWorldCup 2026😀

[SASAKO, Takayoshi @sasakotaka]

I also tried to draw attention to comorbid diabetes and potentially catabolic medications when we manage osteosarcopenia. Please also see our previous case report: https://t.co/VKs8SZoESr #JDI 😌

[SASAKO, Takayoshi @sasakotaka]

https://t.co/JrPe5sryOL @JCSM_cachexia
https://t.co/cWRVG9eKLf @pnas

[SASAKO, Takayoshi @sasakotaka]

I also tried to draw attention to comorbid diabetes and potentially catabolic medications when we manage osteosarcopenia. Please also see our previous case report: https://t.co/VKs8SZoESr 😌

[SASAKO, Takayoshi @sasakotaka]

Please also see: https://t.co/jye3P2d15Y

[Gustavo Duque @DrGustavoDuque]

#Osteosarcopenia Revisited: From #Mechanisms to #Management. A state-of-the-art review prepared by researchers from Japan, Norway, Spain, Australia & Canada. Enjoy your reading: https://t.co/QypODKTdRh @ASBMR @iofbonehealth @aging_CEDurable @MiguelGBorda2 @marc_p_sim @sasakotaka

[SASAKO, Takayoshi @sasakotaka]

https://t.co/cWRVG9eKLf @pnas

[SASAKO, Takayoshi @sasakotaka]

I also tried to draw attention to comorbid diabetes and potentially catabolic medications when we manage osteosarcopenia. Please also see our previous case report: https://t.co/VKs8SZoESr 😌

[SASAKO, Takayoshi @sasakotaka]

https://t.co/JrPe5sryOL @JCSM_cachexia https://t.co/vn3xDp5h7q @NatureComms
https://t.co/PLgYn6Ck8n @pnas

[SASAKO, Takayoshi @sasakotaka]

I am proud that I have been involved in three skeletal muscle-specific KO models of osteosarcopenia: Crif1 KO (mitochondria), AR KO (androgen signaling), and Akt1/2 KO (insulin/IGF-1 signaling).

[SASAKO, Takayoshi @sasakotaka]

Systemic KO models and GWASs in humans tell us about mechanisms shared by osteoporosis and sarcopenia, whereas tissue-specific KO models tell us about how muscle and bone interact with each other.

[SASAKO, Takayoshi @sasakotaka]

In particular, I tried to explore the mechanisms underlying the development of osteosarcopenia by integrating GWAS results in humans and genetically modified mouse models, with 'anabolism' as one of the keywords.